Abstract
Rationale The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established.
Objectives To assess outcomes following COVID-19 in patients with ILD versus those without in a contemporaneous age, sex and comorbidity matched population.
Methods An international multicentre audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death.
Measurements and Main Results Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and comorbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC ≥80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 1.98, 1.13−3.46).
Conclusions Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.
Competing Interest Statement
Dr. Jenkins reports grants from Astra Zeneca, grants from Biogen, personal fees from Boehringer Ingelheim, personal fees from Daewoong, personal fees from Galapagos, grants from Galecto, grants from GlaxoSmithKline, personal fees from Heptares, non-financial support from NuMedii, grants and personal fees from Pliant, personal fees from Promedior, non-financial support from Redx, personal fees from Roche, other from Action for Pulmonary Fibrosis, outside the submitted work. Dr. Russell reports personal fees from Hoffman La Roche, grants from NIHR BRC, during the conduct of the study. Dr. MOLINA-MOLINA reports personal fees from Esteve-Teijin, grants and personal fees from Roche, grants and personal fees from Boehringer Ingelheim, outside the submitted work. Dr. Bendstrup reports grants, personal fees and non-financial support from Boehringer Ingelheim, grants, personal fees and non-financial support from Hoffmann la Roche, outside the submitted work. Prof. Semple reports grants from DHSC National Institute of Health Research UK, grants from Medical Research Council UK, grants from Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, during the conduct of the study; other from Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. Dr. Wells reports personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche Pharmaceuticals, personal fees from Blade. Dr. George reports grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche Pharmaceuticals, personal fees from Teva, outside the submitted work.outside the submitted work. Dr. Castillo reports personal fees and non-financial support from Roche, personal fees and non-financial support from Boehringer-Ingelheim, grants from Fujirebio, outside the submitted work.
Funding Statement
RGJ is supported by an NIHR Research Professor Award (RP-2017-08-ST2-014). LPH is supported by the NIHR Oxford Biomedical Research Centre. This work is supported by grants from: the National Institute for Health Research [award CO-CIN-01], the Medical Research Council [grant MC_PC_19059] and by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], and Liverpool Experimental Cancer Medicine Centre for providing infrastructure support for this research (Grant Reference: C18616/A25153). The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome Trust or PHE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics and Consent Only data that were obtained as part of routine clinical care were collected and entered into the ILD Audit. All data were de-identified and entered by the Local Clinical Care Team in anonymised fashion without linkage to any patient identifiers in line with national and local guidance. In the UK Health Research Authority guidance was followed (https://www.hra.nhs.uk/covid-19-research/guidance-using-patient-data/), and therefore consent and ethical approval was not required. Data for control patients was obtained from the ISARIC4C CCP-UK study, which received ethical approval from the South Central - Oxford C Research Ethics Committee in England (Ref: 13/SC/0149), and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author contributions: RGJ designed and conceived the study and drafted the manuscript. TMD analysed the data and drafted the manuscript. ABD, EMH, JKQ, IS developed the analysis plan and analysed the data and revised the manuscript. LH, GH collated and curated all data and revised the manuscript. HA, SA, SB, CMB, SB, EB, SB, DCV, NC, FC, RC, WC, AC, LEC, DD, CAF, IAF, PG, MAG, KG, SH, SPH, EH, MH, LPH, RKH, JH, KH, MJ, MK, MK, LM, SV, GM, MMM, PLM, AOB, KOR, AP, HP, VP, JP, ER, PRO, AMR, GS, LGS, GMS, HS, SS, DT,MT, TW, KW, AUW, AW, MW, FW, JKB, PJMO, MGS helped design the study, contributed data and revised the manuscript for important intellectual content. SJ helped design study and revised the manuscript for important intellectual content. All authors have provided final approval of the version submitted for publication; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Data Availability
All de-identified, anonymised, and unlinked data from the ILD Audit can be shared on request. ISARIC 4C data can be accessed in line with data sharing policy
